Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration

Table 3 Changes in choroidal thickness, retinal thickness and retinal nerve fiber layer thickness during ranibizumab treatment

	Baseline	3 months	P value*	6 months	P value*
Subfoveal CT (μm)	228.6 ± 78.6	213.8 ± 75.5	<0.001	214.1 ± 72.8	<0.001
Peripapillary CT (μm)
Mean	153.2 ± 45.3	149.6 ± 43.8	0.156	150.0 ± 43.4	0.187
Superior	165.2 ± 49.5	162.2 ± 48.7	0.252	162.6 ± 47.8	0.330
Nasal	153.2 ± 43.0	151.6 ± 43.3	0.532	150.8 ± 42.7	0.378
Inferior	127.3 ± 40.0	125.1 ± 38.3	0.321	125.9 ± 37.5	0.555
Temporal	167.1 ± 54.5	159.4 ± 50.8	0.010	160.6 ± 49.6	0.011
Central RT (μm)	300.4 ± 93.0	233.6 ± 62.0	0.001	232.9 ± 61.9	0.001
Peripapillary RT (μm)
Mean	282.8 ± 19.7	279.9 ± 22.1	0.009	279.8 ± 20.2	0.033
Superior	303.0 ± 28.3	301.6 ± 30.1	0.169	300.7 ± 26.9	0.171
Nasal	250.4 ± 22.1	251.0 ± 26.7	0.732	251.0 ± 22.9	0.812
Inferior	300.4 ± 22.0	300.2 ± 24.8	0.829	298.2 ± 22.7	0.246
Temporal	276.8 ± 21.2	267.0 ± 20.1	<0.001	269.3 ± 21.9	0.015
RNFL thickness (μm)
Mean	111.7 ± 11.4	112.9 ± 10.6	0.666	113.1 ± 11.9	0.611
Superior	130.4 ± 17.5	131.8 ± 16.3	0.736	134.0 ± 16.4	0.373
Nasal	89.3 ± 15.8	92.2 ± 18.9	0.478	90.4 ± 19.3	0.790
Inferior	135.1 ± 16.9	137.9 ± 17.0	0.439	138.6 ± 18.9	0.350
Temporal	92.1 ± 16.2	89.4 ± 13.4	0.379	89.4 ± 16.0	0.385

Continuous variables are expressed as mean ± standard deviation
*Comparison of the parameters in each AMD group visit; P value was based on the paired t-test
CT choroidal thickness, RT retinal thickness, RNFL retinal nerve fiber layer

ISSN: 1471-2415